Effect of pure microsteatosis on transplant outcomes after living donor liver transplantation: A matched case‐control study

Sangbin Han, Justin Sangwook Ko, Gheeyoung Kwon, Cheolkeun Park, Sanghoon Lee, Jongman Kim, Gaabsoo Kim, Choonhyuck David Kwon, Misook Gwak, Sangyun Ha – 14 January 2014 – Liver steatosis mostly exists in a mixed form of macrosteatosis (MaS) and microsteatosis (MiS). This coexistence is responsible for previous conflicting results regarding the importance of MiS in liver transplantation. We aimed to evaluate the independent effect of MiS on posttransplant outcomes with the exclusion of the confounding effect of MaS.

Clinical outcomes of living donor liver transplantation for patients 65 years old or older with preserved performance status

Toru Ikegami, Yuki Bekki, Daisuke Imai, Tomoharu Yoshizumi, Mizuki Ninomiya, Hiromitsu Hayashi, Yo‐Ichi Yamashita, Hideaki Uchiyama, Ken Shirabe, Yoshihiko Maehara – 14 January 2014 – The purpose of this study was to determine the outcomes of living donor liver transplantation (LDLT) for elderly recipients. We reviewed 411 adult‐to‐adult LDLT cases, including 46 recipients who were 65 years old or older and 365 recipients who were less than 65 years old.

Changing etiologies and outcomes of acute liver failure: Perspectives from 6 transplant centers in Argentina

Manuel Mendizabal, Sebastián Marciano, María G. Videla, Margarita Anders, Alina Zerega, Domingo C. Balderramo, Débora Chan, Martín Barrabino, Octavio Gil, Ricardo Mastai, Silvina Yantorno, Adrián Gadano, Marcelo O. Silva – 14 January 2014 – There is significant geographic variation in the etiologies and prognoses of acute liver failure (ALF). The aims of the present study were to determine the causes and short‐term outcomes of ALF in Argentina, to evaluate the performance of prognostic criteria, and to identify clinical prognostic factors of death.

Hepatitis B virus infection enhances susceptibility toward adeno‐associated viral vector transduction in vitro and in vivo

Marianna Hösel, Julie Lucifora, Thomas Michler, Gisela Holz, Marion Gruffaz, Stephanie Stahnke, Fabien Zoulim, David Durantel, Mathias Heikenwalder, Dirk Nierhoff, Rachel Millet, Anna Salvetti, Ulrike Protzer, Hildegard Büning – 14 January 2014 – Gene therapy has become an accepted concept for the treatment of a variety of different diseases. In contrast to preclinical models, subjects enrolled in clinical trials, including gene therapy, possess a history of infection with microbes that may influence its safety and efficacy.

Cost‐effectiveness of sofosbuvir‐based triple therapy for untreated patients with genotype 1 chronic hepatitis C

Salvatore Petta, Giuseppe Cabibbo, Marco Enea, Fabio Salvatore Macaluso, Antonella Plaia, Raffaele Bruno, Antonio Gasbarrini, Antonio Craxì, Calogero Cammà, WEF Study Group – 13 January 2014 – We assessed the cost‐effectiveness of sofosbuvir (SOF)‐based triple therapy (TT) compared with boceprevir (BOC)‐ and telaprevir (TVR)‐based TT in untreated genotype 1 (G1) chronic hepatitis C (CHC) patients discriminated according to IL28B genotype, severity of liver fibrosis, and G1 subtype. The available published literature provided the data source.

Cost‐effectiveness of sofosbuvir‐based triple therapy for untreated patients with genotype 1 chronic hepatitis C

Salvatore Petta, Giuseppe Cabibbo, Marco Enea, Fabio Salvatore Macaluso, Antonella Plaia, Raffaele Bruno, Antonio Gasbarrini, Antonio Craxì, Calogero Cammà, WEF Study Group – 13 January 2014 – We assessed the cost‐effectiveness of sofosbuvir (SOF)‐based triple therapy (TT) compared with boceprevir (BOC)‐ and telaprevir (TVR)‐based TT in untreated genotype 1 (G1) chronic hepatitis C (CHC) patients discriminated according to IL28B genotype, severity of liver fibrosis, and G1 subtype. The available published literature provided the data source.

Subscribe to